NCT06224855View on ClinicalTrials.gov

A Study of DXC006 in Patients With Advanced Solid Tumors and Hematologic Malignancies

PHASE1RecruitingINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

January 24, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Advanced Solid TumorsHematological Malignancies
Interventions
DRUG

DXC006

"Dose escalation period: DXC006 is administered intravenously every two weeks (Q2W) at the dose corresponding to the enrolled dose cohort.~Dose expansion period: DXC006 is administered intravenously Q2W at the corresponding dose."

Trial Locations (1)

510050

RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors
lead

Hangzhou DAC Biotechnology Co., Ltd.

INDUSTRY